Srikanth Venkatraman

SCH 503034, a Mechanism-Based Inhibitor of Hepatitis C Virus NS3 Protease, Suppresses Polyprotein Maturation and Enhances the Antiviral Activity of Alpha Interferon in Replicon Cells

Bruce A. Malcolm, R. Liu, Frederick Lahser et al. · Antimicrobial Agents and Chemotherapy · 2006 · 316 citations · Full text

Viral Replication, Hepatitis C Virus, Immunology +17

Discovery of (1 <i>R</i> ,5 <i>S</i> )- <i>N</i> -[3-Amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]- 3-[2( <i>S</i> )-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2( <i>S</i> )-carboxamide (SCH 503034), a Selective, Potent, Orally Bioavailable Hepatitis C Virus NS3 Protease Inhibitor:  A Potential Therapeutic Agent for the Treatment of Hepatitis C Infection

Srikanth Venkatraman, Stéphane Bogen, Ashok Arasappan et al. · Journal of Medicinal Chemistry · 2006 · 278 citations · Full text

On the Mechanism of the Skraup−Doebner−Von Miller Quinoline Synthesis

Scott E. Denmark, Srikanth Venkatraman · The Journal of Organic Chemistry · 2006 · 205 citations

From Aziridines to Oxazolines and Thiazolines: The Heterocyclic Route to Thiangazole

Peter Wipf, Srikanth Venkatraman · Synlett · 2004 · 137 citations

Heterocyclic Route, Medicinal Chemistry, Oxazoline Intermediates +13

An improved protocol for azole synthesis with PEG-supported Burgess reagent

Peter Wipf, Srikanth Venkatraman · Tetrahedron Letters · 1996 · 106 citations

Combinatorial Chemistry, Azole Synthesis, Engineering +9